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Aspartame Attenuates 2, 4-Dinitroﬂuorobenzene-
Induced Atopic Dermatitis–Like Clinical Symptoms
in NC/Nga Mice
Gun-Dong Kim1, Yong Seek Park1, Hyun-Jong Ahn1, Jeong-Je Cho1 and Cheung-Seog Park1
Atopic dermatitis (AD) is a common multifactorial chronic skin disease that has a multiple and complex
pathogenesis. AD is gradually increasing in prevalence globally. In NC/Nga mice, repetitive applications of 2, 4-
dinitroﬂuorobenzene (DNFB) evoke AD–like clinical symptoms similar to human AD. Aspartame (N-L-α-aspartyl-L-
phenylalanine 1-methyl ester) is a methyl ester of a dipeptide, which is used as an artiﬁcial non-nutritive
sweetener. Aspartame has analgesic and anti-inﬂammatory functions that are similar to the function of
nonsteroidal anti-inﬂammatory drugs such as aspirin. We investigated whether aspartame can relieve AD–like
clinical symptoms induced by DNFB treatment in NC/Nga mice. Sucrose did not relieve AD–like symptoms,
whereas aspartame at doses of 0.5 μg kg− 1 and 0.5 mg kg− 1 inhibited ear swelling and relieved AD–like clinical
symptoms. Aspartame inhibited inﬁltration of inﬂammatory cells including eosinophils, mast cells, and CD4+
T cells, and suppressed the expression of cytokines including IL-4 and IFN-γ, and total serum IgE levels.
Aspartame may have therapeutic value in the treatment of AD.
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INTRODUCTION
Atopic dermatitis (AD) is a serious and chronically relapsing
inﬂammatory skin disorder involving severe pruritus, dryness,
and clinical manifestations such as erythematous, edema, and
licheniﬁcation in skin lesions (Leung and Bieber, 2003). These
clinical symptoms correlate with IgE–mediated sensitization,
increased transepidermal water loss, and cutaneous hyper-
sensitivity that leads to disruption of the skin barrier (Gittler
et al., 2013). The estimated number of AD patients includes
up to 5% of adults and 18% of children worldwide, and the
prevalence has been increasing steadily (Shaw et al., 2011). AD
has a complicated pathogenesis involving genetic, immuno-
logic, and environmental factors, which hinders efﬁcacious
treatment (Leung, 2000). Although long-term application of
steroids can produce side effects that include skin thinning and
atrophy, topical corticosteroid therapy is a common and
effective treatment for AD (Rudikoff and Lebwohl, 1998).
There is a need for new kinds of treatment for AD.
Aspartame (N-L-α-aspartyl-L-phenylalanine 1-methyl ester)
is a methyl ester of a dipeptide used as an artiﬁcial non-
nutritive sweetener. It is marketed as NutraSweet, Canderel,
Sanecta, and Equal (Baines, 1985; Magnuson et al., 2007).
Aspartame is the most widely used synthetic sweetener in
various foods, drugs, and beverages reﬂecting its inexpensive
cost, stability under dry conditions, reduced caloric intake,
marked (150 to 200 times) increased sweetness compared
with traditional sugar, and the absence of proven side effects
(Magnuson et al., 2007). Because of these properties,
aspartame has popularly been used to reduce or maintain
body weight (Pandurangan et al., 2014). Aspartame also
signiﬁcantly reduces lipid accumulation and expression of
peroxisome proliferator–activated receptor γ, fatty acid–
binding protein 4, CCAAT/enhancer-binding protein α, and
sterol regulatory element–binding protein 1 during 3T3-L1
differentiation without signiﬁcant toxic effects (Pandurangan
et al., 2014).
Aspartame has analgesic functions that are similar to the
function of nonsteroidal anti-inﬂammatory drugs (NSAIDs)
such as aspirin. These functions include increased motor
activity and attenuated mechanical hyperalgesia in a
carrageenan-elicited monoarthritis murine model (LaBuda
and Fuchs, 2001). Aspartame also reportedly reduces lipopol-
ysaccharide-stimulated IL-6, which is a recognized biomarker
of the inﬂammatory response, and it slightly increases the
anti-inﬂammatory cytokine IL-10 in human whole-blood
cultures (Rahiman and Pool, 2014). Although there is no
direct evidence for the anti-inﬂammatory functions of
aspartame, it may involve the inhibition of prostaglandin H2
synthesis and cyclooxygenases. Computer-assisted virtual
modeling has shown that aspartame is a suitable ligand for
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human Bence–Jones dimer, which represents an Ig light
chain (Edmundson and Manion, 1998). This complex of
aspartame and the Bence–Jones dimer have been closely
matched to the active site of the cyclooxygenase portion
of prostaglandin H2 synthase-1 and they interact with
IgM rheumatoid factors (Edmundson and Manion, 1998;
Rahiman and Pool, 2014). In patients with rheumatoid
arthritis, osteoarthritis, treatment with aspartame increased
bleeding time, relieved pain, and improved performance
including walking, climbing, and grip strength (Edmundson
and Manion, 1998).
We hypothesized that the analgesic effect of aspartame
may attenuate AD symptoms. Therefore, we investigated the
therapeutic effects of aspartame on AD–like skin lesions.
RESULTS
Aspartame ameliorates DNFB-induced AD–like clinical
manifestations
Repetitive application of 2, 4-dinitroﬂuorobenzene (DNFB)
induced AD–like clinical symptoms in NC/Nga mice
(Jin et al., 2009). Aspartame ameliorates mechanical
hyperalgesia in a carrageenan-induced monoarthritis model
(LaBuda and Fuchs, 2001). Thus, we investigated the
therapeutic effects of aspartame on DNFB-induced AD–like
symptoms and responses. Mice were randomly divided into
ﬁve groups. Mice were sensitized by 0.2% DNFB on days 3
and 6, and then they were further challenged with 0.3%
DNFB on days 9, 12, and 15 (Figure 1a). The effects of
aspartame treatment were then macroscopically assessed at
Day 0 Day 3 Day 6 Day 9 Day 12 Day 15 Day 18
Aspartame 0.5 μg kg–1 and 0.5 mg kg–1
Shaving 0.2% DNFB treatment 0.3% DNFB treatment Killed
After 5th treatment
DNFB
Sucrose
Aspartame
–
– –
+ + + +
– – –
– –
0.5 mg/kg
0.5 mg/kg
0.5 μg/kg
Groups SCORAD No. of mice
DNFB (–)
DNFB (+) SUC 0.5 mg/kg
DNFB (+) ASP 0.5 mg/kg
DNFB (+) ASP 0.5 μg/kg
DNFB
5
5
5
5
5
0 ± 0.00
9.83 ± 1.09
8.33 ± 1.08 *
6.00 ± 1.29 ***
5.33 ± 1.25 ***
a
b
c
Figure 1. Aspartame (ASP, N-L-α-aspartyl-L-phenylalanine 1-methyl ester) relieves 2, 4-dinitroﬂuorobenzene (DNFB)-induced atopic dermatitis (AD)–like
symptoms. (a) AD–like lesions were induced by repetitive painting of 0.2% DNFB (acetone:olive oil, 3:1) on the dorsal skin of NC/Nga mice once daily on days 3
and 6, with further challenge with 0.3% DNFB on days 9, 12, and 15. (b) Representative dorsal skin photographs captured after the ﬁfth treatment depict AD–like
skin lesions with and without Aspartame (n=5 in each group). (c) AD severity was macroscopically evaluated by SCORAD (SCORing Atopic Dermatitis). Overall
dermatitis score was determined from the sum of all individual scores. Data are presented as mean± SEM of ﬁve determinations. *Po0.05, ***Po0.001 vs. DNFB
(+) groups. SUC, sucrose.
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the site of DNFB-induced AD–like skin lesions. The accep-
table daily intake level of aspartame in humans is 40 and
50mg kg− 1 of body weight according to the European Food
Safety Authority and US Food and Drug Administration,
respectively (Magnuson et al., 2007). At present, continual
repetitive application of DNFB-induced AD–like skin lesions
involving severe clinical manifestations including erythema,
edema, oozing, excoriation, crust, and licheniﬁcation in NC/
Nga mice. Daily oral administration of 0.5 mg kg−1 sucrose
was not therapeutic, whereas oral administration of 0.5
μg kg−1 and 0.5 mg /kg−1 aspartame relieved AD–like skin
lesions compared with the DNFB-treated group (Figure 1b).
DNFB-evoked ear swelling was closely correlated with
relapsing edema and oozing, and this response was sig-
niﬁcantly suppressed by aspartame in a concentration-
dependent manner (Figures 1 and 2a).
Aspartame inhibits inﬁltration of inﬂammatory cells to AD–like
skin lesions
Repetitive applications of DNFB markedly disturb the
epidermal barrier and induce adhesion molecules. Levels of
various immune mediators are increased by DNFB treatment,
which induce the cytokine cascade and increase epidermal
leukocyte density that leads to leukocyte rolling and inﬁltra-
tion of inﬂammatory cells (Proksch and Brasch, 1997; Deane
and Hickey, 2009). Increasing numbers of FcεRI (high afﬁnity
Immunoglobulin E receptor)-expressing eosinophils and
mast cells have an important role in developing chronic
AD (Abboud et al., 2009). In AD, inﬁltrated eosinophils
secrete lipid mediators, toxic granule proteins, cytokines, and
enzymes including eosinophil peroxidase, and major basic
protein that induces tissue damage and inﬂammation in skin
lesions (Wakita et al., 1994). Therefore, we examined the
effect of aspartame on dermal inﬁltration of eosinophils in
AD–like skin lesions in NC/Nga mice. DNFB induced
enormous inﬁltration of eosinophils and dermal thickness in
ear and dorsal skin lesions (Figures 2 and 3). Sucrose at a dose
of 0.5 mg kg−1 did not suppress inﬁltration of inﬂammatory
cells and hyperkeratosis in AD–like skin lesions. Both
aspartame concentrations inhibited inﬁltration of eosinophils
and suppressed epidermal thickening. Activation of mast cells
through the FcεRI receptor by allergen-sensitized IgE leads to
the release of various granular mediators, cytokines, and
chemokines including prostaglandins, leukotrienes, platelet-
activating factor, IL-13, and eotaxin, which are associated
with the development of AD (Amon et al., 1994). Thus, we
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Figure 2. Aspartame (ASP, N-L-α-aspartyl-L-phenylalanine 1-methyl ester) reduces increasing ear swelling and epidermal thickness. (a) Ear swelling was
measured daily with a thickness gauge. Aspartame and sucrose (SUC) were orally administered at doses of 0.5 μg kg−1 or 0.5 mg kg−1. Five mice were placed
into each of ﬁve groups: 2, 4-dinitroﬂuorobenzene (DNFB) (− ; acetone:olive oil, 3:1); DNFB (+; acetone:olive oil, 3:1 with 0.2–3% DNFB); DNFB with sucrose,
0.5 mg kg−1; DNFB with aspartame, 0.5 μg kg− 1; and DNFB with aspartame, 0.5 mg kg−1. (b) Skin sections were hematoxylin and eosin–stained (n= 10).
(c) Bar= 100 μm. Data are presented as mean± SEM of ﬁve determinations. *Po0.05, **Po0.01, ***Po0.001 vs. DNFB (+) groups.
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examined the suppressive effect of aspartame on
degranulation and inﬁltration of mast cells in DNFB-induced
AD–like skin lesions using toluidine blue staining. Both
concentrations of aspartame reduced mast cell inﬁltration and
degranulation, whereas 0.5 mg kg−1 sucrose did not
(Figure 4). T lymphocytes have important roles for the
development of AD—that is, as a critical source of Th2
cytokines, such as IL-4, IL-5, and IL-13, which are important
to IgE synthesis and eosinophil accumulation in AD–like skin
lesions (Novak et al., 2004). We examined whether aspartame
inhibited inﬁltration of T lymphocytes in AD–like skin lesions
using immunoﬂuorescence. Sucrose did not suppress
inﬁltration of T lymphocytes, whereas aspartame inhibited
inﬁltration of CD4+ T cell numbers in dorsal skin lesions in
NC/Nga mice (Figure 5).
Aspartame suppresses inﬂammatory cytokine synthesis by
activated CD4+ T cells of DNFB-induced AD–like skin lesions
AD is characterized by two distinct phases, the chronic and
acute phases, resulting in either T helper type 1 (Th1) or T
helper type 2 (Th2) dominant inﬂammation. Th1 dominant
inﬂammation is mainly affected by Th1 cells and their
production of IL-2 and IFN-γ, whereas IL-4, IL-5, and IL-13
are produced by Th2 cells that affect Th2 dominant
inﬂammation (Leung, 2000). IL-2 and IFN-γ contribute to
hyperkeratosis and dermal thickening that leads to the chronic
phase of AD. Th2 cytokines induce the synthesis and
secretion of IgE and accumulation of inﬂammatory cells in
AD–like skin lesions, which also lead to the development of
the chronic phase of AD. Therefore, we investigated whether
aspartame affects the Th1 or Th2 responses of CD4+ T cells in
the AD–like NC/Nga mouse model. Aspartame inhibited the
inﬁltration of CD4+ T cells in DNFB-induced AD–like dorsal
skin lesions (Figure 5). Furthermore, production of IL-4 and
IFN-γ decreased in mice treated with either concentration of
aspartame compared with that in DNFB-treated mice and
0.5 mg kg−1 sucrose-treated mice (Figure 6a and b).
Aspartame suppresses DNFB-induced serum IgE synthesis
In allergic inﬂammation, IgE is synthesized by B cells and
induces the activation of mast cells through FcεRI, leading to the
secretion of Th2 cytokines and histamine (Kim et al., 2012).
Because abundant synthesis of total serum IgE is a hallmark of
AD (Leung, 2000), we prepared serum samples to assess total
serum IgE and dinitrophenyl (DNP)-speciﬁc IgE levels using
an ELISA. Consistent with other studies (Yamaguchi et al.,
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Figure 3. Aspartame (ASP, N-L-α-aspartyl-L-phenylalanine 1-methyl ester) inhibits inﬁltration of eosinophils in atopic dermatitis (AD)–like skin lesions. (a) Skin
sections were hematoxylin and eosin (H&E) stained (n= 10). (b) Eosinophils in H&E–stained sections were counted under a microscope, and the numbers of
inﬁltrated eosinophils were expressed as average total counts in three ﬁelds of 100 μm2. (c) Bar=100 μm. The number of cells is expressed as the mean± SEM of
ﬁve sections. Arrows indicate eosinophils. *Po0.05, **Po0.01, ***Po0.001 vs. DNFB (+) groups. SUC, sucrose.
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1999), increased production of IL-4 and the inﬁltration and
degranulation of mast cells were associated with IgE produc-
tion, and both of these effects were suppressed by both
concentrations of aspartame (Figures 4 and 6a). Oral
administration of either concentrations of aspartame inhibited
total serum IgE and DNP-speciﬁc IgE levels as compared with
DNFB alone and sucrose-treated groups in the AD–like NC/
Nga models (Figure 6c and d).
DISCUSSION
AD is a common chronic inﬂammatory skin disorder
characterized by relapsing clinical manifestations including
edema, erythema, scaling, and pruritus that severely impairs
the quality of life of patients and family members (Galli et al.,
2003). Although topical steroid therapy is the most effective
remedy for AD, continual repetitive application of steroids
leads to side effects that include skin thinning and atrophy
(Del Rosso and Friedlander, 2005). Therefore, a combination
therapy including emollient, antimicrobial, and anti-
inﬂammatory approaches is currently the preferred treatment
goal for AD patients (Wollenberg and Schnopp, 2010).
Aspartame (N-L-α-aspartyl-L-phenylalanine 1-methyl ester)
is the most widely used artiﬁcial non-nutritive sweetener in
various beverages, foods, and drugs. Aspartame is 150 to 200
times sweeter than sucrose without proven side effects
(Magnuson et al., 2007). It is metabolized to phenylalanine,
aspartic acid, and some harmful agents including methanol or
formaldehyde (Bell and Labuza, 1991). However, methanol is
metabolized in the liver to formaldehyde, which is rapidly
metabolized to formic acid with a half-life of only to 2min,
because formaldehyde does not accumulate in the body
(Barceloux et al., 2002).
Aspartame has not shown harmful effects in vivo in doses
up to 1600mg kg− 1 body weight per day on chromosomes of
bone marrow or spermatogonial cells in rats (Bowles, 1970).
Another study demonstrated that aspartame at concentrations
of 25, 50, and 100mg kg−1 has analgesic and anti-
inﬂammatory effects in carrageenan-induced rat model of
monoarthritis (LaBuda and Fuchs, 2001). Treatment with
10 μgml−1 aspartame was reported to inhibit lipopolysac-
charide-stimulated IL-6, whereas production of IL-10 was
slightly increased in human whole-blood cultures (Rahiman
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Figure 4. Aspartame (ASP, N-L-α-aspartyl-L-phenylalanine 1-methyl ester) suppresses degranulation and inﬁltration of mast cells in atopic dermatitis (AD)–like
skin lesions. (a) 2, 4-Dinitroﬂuorobenzene (DNFB) (− ), DNFB (+), DNFB+sucrose (SUC) (0.5 mg kg−1), DNFB+aspartame (0.5 μg kg−1), and DNFB+aspartame
(0.5 mg kg−1) treated. Mast cells in toluidine blue–stained sections were counted under a microscope. (b) Degranulated mast cells were expressed as average
total counts in three ﬁelds of 100 μm2 (n= 5 sections each). (c) Bar= 100 μm; the number of cells is expressed as the mean± SEM of ﬁve sections. Both black and
red arrows indicate mast cells and degranulated mast cells. *Po0.05, ***Po0.001 vs. DNFB (+) groups.
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and Pool, 2014). Aspartame interference with the formation of
complexes between normal human IgG Fc and IgM-type
rheumatoid factor was described (Ramsland et al., 1999). This
decreasing rheumatoid factor activity leads to relived pain and
improved performance involving walking and grip strength in
patients with osteoarthritis (Edmundson and Manion, 1998).
These observations collectively indicate the potential value
of aspartame for the treatment of AD. We investigated the
effect of aspartame on the severity of AD–like clinical
symptoms in DNFB-induced AD–like lesions. Treatment of
mice with 0.5 μg kg− 1 and 0.5 mg kg− 1 aspartame signiﬁ-
cantly relieved AD–like clinical manifestations including
erythema, edema, excoriation, and hyperkeratosis compared
with sucrose- and DNFB-treated groups (Figure 1b and c).
Furthermore, DNFB-induced ear swelling was partially
inhibited by aspartame (Figure 2).
Repetitive application of DNFB disturbs the physical
barrier of the skin and induces the expression of various
adhesion molecules, such as vascular cell adhesion mole-
cule and intracellular adhesion molecule, on the surface
of inﬂammatory cells including eosinophils, mast cells, and
T lymphocytes (Deane and Hickey, 2009). The secretion of
various immune mediators induces the cytokine cascade and
promotes accumulation of collagen, which preludes dermal
thickening and increasing tissue damage (Barker et al., 1991;
Proksch and Brasch, 1997; Purwar et al., 2008). Continual
treatment of DNFB induced increased epidermal thickness
and inﬁltration of eosinophils in ear and dorsal skin (Figures 2
and 3). Treatment with 0.5 mg kg−1 sucrose did not produce
inhibition, whereas 0.5 μg kg− 1 and 0.5 mg kg− 1 aspartame
reduced the increased epidermal thickness and inﬁltration of
eosinophils.
Allergen-sensitized IgE activates mast cells, leading to
the development of Th2 cells and secretion of cytokines,
chemokines, prostaglandins, and platelet-activating factor,
which in turn induce the development of AD–like skin lesions
(Harvima et al., 1994). Aspartame (0.5 μg kg−1 and
0.5 mg kg−1) inhibited mast cell degranulation and inﬁltrat-
ing mast cells, whereas sucrose did not (Figure 4). Degranula-
tion and inﬁltration of activated mast cells is related to either
the production of inﬂammatory cytokines by activated
T lymphocytes or increasing IgE synthesis. To investigate
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Figure 5. Aspartame (ASP, N-L-α-aspartyl-L-phenylalanine 1-methyl ester) inhibits inﬁltration of CD4+ T cells in atopic dermatitis (AD)–like skin lesions.
NC/Nga mice were treated with 0.2% 2, 4-dinitroﬂuorobenzene (DNFB) (acetone:olive oil, 3:1) on shaved back skin on days 3 and 6, and further challenged with
0.3% DNFB on days 9, 12, and 15. Aspartame was orally administered daily from the day of ﬁrst DNFB challenge (day 9). On day 18, immunoﬂuoroscence
staining was performed with the cryosections of dorsal skin samples with Alexa Fluor 488–conjugated goat anti-rat antibody. Representative picture showing
activation of CD4+ T cells. (a) After DNFB treatment, which was inhibited by aspartame. (b) Merged CD4+ T cells were counted. The number of cells is expressed
as the mean± SEM of ﬁve sections. Arrows indicate merged cells. **Po0.01, ***Po0.001 vs. DNFB (+) groups. Bar=100 μm. SUC, sucrose.
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whether aspartame suppressed inﬁltration of T lymphocytes in
AD–like skin lesions, immunoﬂuorescence examination was
carried out on dorsal skin lesions. Oral administration of
0.5 μg kg− 1 and 0.5 mg kg− 1 aspartame inhibited the number
of inﬁltrating CD4+ T cells (Figure 5). In allergic inﬂammation,
Langerhans cell primed allergen speciﬁc naive T cells in
draining lymph nodes develop into proallergic cells and home
to the skin lesions, which is followed by the production of
inﬂammatory cytokines (Dubrac et al., 2010). To investigate
whether aspartame regulates the cytokine production of CD4+
T cells in dermal skin lesions, we performed ELISA. Continual
treatment of DNFB markedly induced the production of IL-4
and IFN-γ by activated CD4+ T cells. However, 0.5 μg kg−1
and 0.5 mg kg− 1 aspartame signiﬁcantly suppressed both IL-4
and IFN-γ production (Figure 6a and b). Whether aspartame
inhibited cytokine production by activated CD4+ T cells was
not examined. However, suppressed inﬁltration of T lymphocytes
might be correlated with decreasing cytokine production.
Th2 cytokines including IL-4, IL-5, and IL-13 produced by
activated T lymphocytes are pivotal in IgE synthesis and
eosinophil inﬁltration in AD–like skin lesions. In particular,
IL-4 is critical to the rearrangement of variable diversity by
joining to Cγ4 or Cε in B cells (Bacharier and Geha, 2000).
Total serum IgE levels and DNP-speciﬁc IgE levels were
increased by DNFB in NC/Nga mice (Figure 6c and d).
Treatment with 0.5 mg kg− 1 sucrose did not reduce IgE
synthesis, whereas mice treated with either aspartame
concentration displayed signiﬁcantly reduced production of
total serum IgE and DNP-speciﬁc IgE in a concentration-
dependent manner (Figure 6c and d).
Molecular mechanisms for the therapeutic effects of
aspartame in AD–like models have not been fully identiﬁed.
The present study suggests that aspartame may be used as a
potential therapeutic compound for AD based on its analgesic
functions and suppression of inﬂammation in AD–like NC/
Nga mice. Further studies are necessary to investigate the
mechanisms whereby aspartame regulates inﬂammatory
mediator release that correlates with analgesic functions
observed in the NC/Nga AD–like model.
MATERIALS AND METHODS
Animals
Seven-week-old NC/Nga male mice (19–22 g) were purchased from
Japan SLC (Shizuoka, Japan) and maintained under speciﬁc
pathogen-free conditions. The mice were housed in an air-
conditioned animal room at a temperature of 25± 1 °C and a relative
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Figure 6. Aspartame (ASP, N-L-α-aspartyl-L-phenylalanine 1-methyl ester) decreases cytokine production of activated CD4+ T cells and reduces total serum IgE
levels. (a) After the mice were killed on day 18, lymph nodes draining the site of injection were excised, then evaluated of weights, and CD4+ T cells were
puriﬁed. (b) Puriﬁed CD4+ T cells (1× 106 cells per ml) were stimulated with anti-CD3 antibody and anti-mouse CD28 antibody for 72 h. Production of IL-4 and
IFN-γ after T cell activation was quantiﬁed by ELISA. (c) Total IgE and (d) dinitrophenyl (DNP)-speciﬁc IgE in the indicated groups were measured 24 h after ﬁnal
administration. 2, 4-Dinitroﬂuorobenzene (DNFB) (− ), DNFB (+), DNFB+sucrose (SUC) (0.5 mg kg−1), DNFB+aspartame (0.5 μg kg−1), and DNFB+aspartame
(0.5 mg kg−1) treated. Results are based on triplicate experiments. Data are mean± SEM (n=5). *Po0.05, **Po0.01, ***Po0.001 vs. DNFB (+) groups.
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humidity of 40± 5%, and they were fed a distilled water and
laboratory diet. Animal treatment and maintenance complied
with the Principles of Laboratory Animal Care (NIH Publication
No. 85-23, revised in 1985) and with the guidelines issued by the
ethics committee for animal welfare at Kyung Hee University
(KHUASP (SE)-15-021). All procedures were conducted in accor-
dance with the United States National Institute of Health guidelines.
Drug treatment
Mice were randomly assigned to ﬁve treatment groups: untreated
(control) group, DNFB-treated group, DNFB with 0.5 mg kg− 1
sucrose, DNFB with 0.5 μg kg− 1 aspartame, and DNFB with 0.5
mg kg−1 aspartame (n= 5 per group). Aspartame and sucrose were
dissolved with distilled water to a volume of 200 μl. The untreated
group and the DNFB group were treated with the same volume of
distilled water. Sucrose and aspartame were given orally every day
from days 9 to 17.
Allergen sensitization and challenge
DNFB sensitization was induced by the repeated application of 25 μl
of 0.2% DNFB in acetone/olive oil (3:1) to the inner and outer
surfaces of the right ear, and 100 μl of the same solution was applied
to shaved dorsal skin once on days 3 and 6. On days 9, 12, and 15,
sensitized mice were challenged with 0.3% DNFB to the dorsal and
right ear skin surfaces. Control mice were treated with the same
volume of vehicle. Increasing ear thicknesses were measured by a
Digimatic Indicator thickness gauge (Mitsutoyo, Tokyo, Japan).
Dermatitis score
The severity of AD–like clinical manifestations was macroscopically
evaluated by the SCORAD (SCORing Atopic Dermatitis) method
(Oranje et al., 2007). The degree of each symptom was graded from 0
to 3 (0, absence; 1, mild; 2, moderate; 3, severe). This scoring was
based on the severity of edema, erythema, oozing, crust, excoriation,
and licheniﬁcation. Overall dermatitis score was determined from the
sum of all individual scores. Assessment was performed by an
investigator who was blind to the grouping of the animals.
Measurement of cytokine production
T lymphocytes were isolated from draining lymph nodes of mice, and
CD4+ T cells were puriﬁed using a Biomag separation column
(Qiagen, Hilden, Germany) according to the manufacturer’s instruc-
tions. Isolated CD4+ T cells (1× 106) were cultured in 24-well ﬂat-
bottom culture plates in RPMI-1640 medium with 50 μM β-
mercaptoethanol and 10% heat-inactivated fetal bovine serum, and
then stimulated with 5 μgml− 1 immobilized anti-CD3 and 2 μgml− 1
soluble anti-CD28 antibody for 72 h at 37 °C in a 5% CO2
atmosphere. After incubation, culture supernatants were collected
and the production of IL-4 and IFN-γ was quantiﬁed by ELISA
(Biolegend, San Diego, CA).
Measurement of total and DNP-speciﬁc IgE
On day 18, total serum samples were prepared and quantiﬁed using
OptEIA Set Mouse IgE ELISA Kits (BD Pharmingen, San Diego, CA)
and mouse anti-DNP IgE ELIAS Kits (Alpha Diagnostic International,
San Antonio, TX) according to the manufacturer’s instructions. The
absorbance was immediately read at 450 nm on an EL 800 ELISA
Reader (Bio-Tek, Winooski, VT).
Histological analysis
On day 18, right ears and dorsal skins were removed and ﬁxed with
4% paraformaldehyde in phosphate-buffered saline (pH 7.4). Fixed
tissues were washed in 30% sucrose solution and frozen in OCT
compound. Cryostat sections (8 μm) were mounted on slides and
dried overnight at room temperature before being ﬁxed in ice-cold
acetone for 5 min. Slides were rehydrated in phosphate-buffered
saline and blocked with 5% normal goat serum in phosphate-
buffered saline containing 0.3% Tween-20 (washing buffer) for 2 h at
room temperature. After washing, sections were incubated with
primary anti-CD4 antibody overnight at 4 °C, washed, and incubated
with Alexa Fluor 488–conjugated goat anti-rat antibody for 6 h at
4°C. Cell nuclei were counterstained with 4′,6-diamidino-2-pheny-
lindole for 4 h at 4 °C. Sections were mounted and images were
captured using an Eclipse 50i ﬂuorescence microscope (Nikon,
Tokyo, Japan). Skin sections (8 μm) from parafﬁn blocks were also
stained with hematoxylin and eosin for inﬂammatory cells, and mast
cells were stained using toluidine blue. Numbers of CD4+ T cells,
eosinophils, and mast cells were expressed as average total counts in
three ﬁelds of 100 μm2 (×200).
Statistical analyses
Data are presented as the mean± SEM of at least three independent
experiments performed in triplicate. Statistical analysis was per-
formed using one-way analysis of variance followed by Bonferroni’s
multiple comparison test. When not shown, error bars lie within
symbols. P-values of o0.05, o0.01, ando0.001 were considered
statistically signiﬁcant.
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